# Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria

Study · id `cardio:ct-nct03449199` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03449199](<https://clinicaltrials.gov/study/NCT03449199>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03449199

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 130 participants.

## Technical summary

Registry record NCT03449199. Randomized; quadruple masking; primary purpose treatment. Start 2018-04-10 (actual); primary completion 2019-05-07 (actual). Results posted on 2022-08-01.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 130 participants (enrolled count; ClinicalTrials.gov record NCT03449199, source copy `cardio:ctgov-nct03449199-2022-08-30`, retrieved 2026-10-26)
- Started: 2018-04-10 (actual) (ClinicalTrials.gov record NCT03449199, source copy `cardio:ctgov-nct03449199-2022-08-30`, retrieved 2026-10-26)
- Primary completion: 2019-05-07 (actual) (ClinicalTrials.gov record NCT03449199, source copy `cardio:ctgov-nct03449199-2022-08-30`, retrieved 2026-10-26)
- Completion: 2019-06-04 (actual) (ClinicalTrials.gov record NCT03449199, source copy `cardio:ctgov-nct03449199-2022-08-30`, retrieved 2026-10-26)
- Results first posted: 2022-08-01 (ClinicalTrials.gov record NCT03449199, source copy `cardio:ctgov-nct03449199-2022-08-30`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03449199, source copy `cardio:ctgov-nct03449199-2022-08-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03449199-2022-08-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria
- Condition: Diabetic Kidney Disease
- Intervention (Drug): TMX-049
- Intervention (Drug): Placebo
- Lead sponsor: Teijin America, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: A Non-purine Xanthine Oxidoreductase Inhibitor Reduces Albuminuria in Patients with DKD: A Randomized Controlled Trial (`cardio:pubmed-35369650`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: a585660d577360f739d2b16aed485bd69150089f9f65bb10b9f59a9cd1e0b459
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
